Alzamend Neuro Inc reports results for the quarter ended in October - Earnings Summary

Alzamend Neuro

15/12/2023 22:38

* Alzamend Neuro Inc  ALZN.OQ  reported a quarterly adjusted
loss
of 44 cents​​ per share for the quarter ended in October, higher
than the same quarter last year, when the company reported EPS
of -45 cents.  The mean expectation of two analysts for the
quarter was for a loss of 67 cents per share. Wall Street
expected results to range from -75 cents to -60 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Alzamend Neuro Inc's reported EPS for the quarter was a
loss
of 44 cents​.
    * The company reported a quarterly loss of $2.91 million.
    * Alzamend Neuro Inc shares had fallen by 70.5% this
quarter and
lost 87.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 12.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Alzamend Neuro
Inc is $56.25 
This summary was machine generated from LSEG data December 15 at
10:37 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Oct. 31 2023      -0.67          -0.44          Beat
 Jul. 31 2023      -0.52          -0.60          Missed
 Apr. 30 2023      -0.67          -0.45          Beat
 Jan. 31 2023      -0.60          -0.90          Missed